



The Role of Microglia in Glioblastoma

Noelia Geribaldi-Doldán^{1,2}, Cecilia Fernández-Ponce^{2,3}, Roberto Navarro Quiroz⁴, Ismael Sánchez-Gomar^{2,3}, Lorena Gómez Escorcía^{5,6}, Erika Puentes Velásquez⁵ and Elkin Navarro Quiroz^{5,6*}

¹ Departamento de Anatomía y Embriología Humanas, Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain, ² Instituto de Investigación e Innovación Biomédica de Cádiz (INIBICA), Cádiz, Spain, ³ Departamento de Biomedicina, Biotecnología y Salud Pública. Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain, ⁴ CMCC-Centro de Matemática, Computação e Cognição, Laboratório de Biologia Computacional e Bioinformática-LBCB, Universidade Federal do ABC, Sao Paulo, Brazil, ⁵ Faculty of Basic and Biomedical Sciences, Universidad Simón Bolívar, Barranquilla, Colombia, ⁶ Centro de investigación e innovación en Biomoléculas, Care4You, Barranquilla, Colombia

OPEN ACCESS

Edited by:

Natanael Zarco,
Mayo Clinic, United States

Reviewed by:

Cornelis Johannes
Forrendinis Van Noorden,
Amsterdam University Medical Center
(UMC), Netherlands
Maria Caffo,
University of Messina, Italy

*Correspondence:

Elkin Navarro Quiroz
elkin.navarro@unisimon.edu.co

Specialty section:

This article was submitted to
Neuro-Oncology and
Neurosurgical Oncology,
a section of the journal
Frontiers in Oncology

Received: 07 September 2020

Accepted: 24 November 2020

Published: 29 January 2021

Citation:

Geribaldi-Doldán N, Fernández-Ponce C,
Quiroz RN, Sánchez-Gomar I,
Escorcía LG, Velásquez EP and
Quiroz EN (2021) The Role of
Microglia in Glioblastoma.
Front. Oncol. 10:603495.
doi: 10.3389/fonc.2020.603495

Glioblastoma (GB), the most aggressive malignant glioma, is made up of a large percentage of glioma-associated microglia/macrophages (GAM), suggesting that immune cells play an important role in the pathophysiology of GB. Under physiological conditions, microglia, the phagocytes of the central nervous system (CNS), are involved in various processes such as neurogenesis or axonal growth, and the progression of different conditions such as Alzheimer's disease. Through immunohistochemical studies, markers that enhance GB invasiveness have been shown to be expressed in the peritumoral area of the brain, such as Transforming Growth Factor α (TGF- α), Stromal Cell-Derived Factor 1 (SDF1/CXCL12), Sphingosine-1-Phosphate (S1P) and Neurotrophic Factor Derived from the Glial cell line (GDNF), contributing to the increase in tumor mass. Similarly, it has also been described 17 biomarkers that are present in hypoxic periarteriolar HSC niches in bone marrow and in hypoxic periarteriolar GSC niches in glioblastoma. Interestingly, microglia plays an important role in the microenvironment that supports GB progression, being one of the most important focal points in the study of therapeutic targets for the development of new drugs. In this review, we describe the altered signaling pathways in microglia in the context of GB. We also show how microglia interact with glioblastoma cells and the epigenetic mechanisms involved. Regarding the interactions between microglia and neurogenic niches, some authors indicate that glioblastoma stem cells (GSC) are similar to neural stem cells (NSC), common stem cells in the subventricular zone (SVZ), suggesting that this could be the origin of GB. Understanding the similarities between SVZ and the tumor microenvironment could be important to clarify some mechanisms involved in GB malignancy and to support the discovering of new therapeutic targets for the development of more effective glioblastoma treatments.

Keywords: glioblastoma, microglia, signaling pathways, therapeutic target, epigenetic

INTRODUCTION

Among primary brain tumors, glioblastoma (GB) has been described as the most aggressive and is generally associated with a poor prognosis (1). GB is commonly treated with a combination of elements, starting with surgery and followed by radio- and chemo-therapy (2). However, the life expectancy of patients is reduced to approximately 15 months, and they face a high likelihood of the cancer recurring (3). New approaches for the treatment of newly diagnosed and recurrent GB such as Tumor Treating Fields (TTF), have shown a prolonged survival in these patients up to 20 months (4). In addition, GB therapies based on engineering Chimeric Antigen Receptors (CARs) have emerged as an immunotherapeutic approach with high specificity for target tumorigenic cells, but with some adverse effects that must be well defined, in order to design effective control strategies (5).

GB is classified as a grade IV glioma due to its patterns of histological necrosis and vascular changes (6). GB is composed of different types of cells, including glioblastoma stem cells (GSCs) that are responsible for tumor malignancy and expansion (7). Other types of cells that are also present in the tumor mass include NK cells, plasma cells, B cells, gamma delta ($\gamma\delta$) T cells, regulatory T cells (Treg), Follicular helper T (Tfh) cells, Th1, Th17, Th2, naïve CD8+ T cells, EMRA CD8+ T cells, effector memory CD8+ T cells, central memory CD8+ T cells, plasmacytoid dendritic cells, granulocytes, dendritic cells, monocytic cells, macrophages type 2 and type 1, which are the most common cells in GB (8–11). Hira et al. demonstrated that GSC niches are located close to tunica adventitia of a small subset of arterioles in hypoxic areas in GB. Thus, the hypoxic condition of GSH niches promotes the conservation of stem cells (12).

Microglia cells are the resident macrophages in the central nervous system (CNS) and could respond to tumorigenesis signaling by producing chemokines and cytokines that favor tumor progression (1, 13, 14). Glioma-associated microglia/macrophages (GAMs) are abundant in the tumor mass and favor tumor progression (15–17). In the tumor, microglia cells can polarize into two different phenotypes, the typical M1 and M2 phenotype (18). The M1 phenotype is functionally distinguished by its ability to eliminate microorganisms or tumor cells, and to secrete proinflammatory cytokines, such as IL-23, IL-12, IL-6, IL-1 β , tumor necrosis factor α (TNF- α), with production of reactive oxygen species (ROS), and a low expression of IL-10 favoring the polarization of T helper cells to Th1 lymphocytes (19, 20); while M2 phenotype is characterized by a low expression of MHC-II, IL-12, IL-23 and a high expression of arginase 1 (Arg1) and anti-inflammatory cytokines, such as TGF- β and IL-10. Thus, M2 phenotype is associated with prolonged neural survival, restriction of brain damage, and prevention of destructive immune responses (21, 22). It has been shown that human GB has a heterogeneous population of M1/M2 macrophages, and M1:M2 ratio is associated with a better prognosis in IDH1 R132H wild-type GB (23). Using automated quantitative immunofluorescence Sørensen et al. found that M2-like TAMs (Tumor associated macrophages) show worse progression in high-grade gliomas

and these favor a pro-tumorigenic microenvironment (24). This negative correlation was corroborated by Caponegro et al. (25) and Zhou et al. (26).

Nowadays researchers are focused on discovering the underlying mechanisms of this awful disease, understanding its biology, and researching therapeutic targets to alleviate the symptoms associated with GB, one of which could involve microglial cells' interactions within the tumor origin and the epigenetics associated therewith.

NEURAL STEM CELLS, MICROGLIA, AND GLIOBLASTOMA STEM CELLS: INTERACTIONS IN THE NEUROGENIC NICHE

Neurogenesis is the action through which the neurons are generated out of neural stem cells (NSCs). This process occurs during the embryonic stage and during adulthood where neurogenesis is relegated to two principal regions in the mammalian brain. These specific neurogenic sites are the dentate gyrus of the hippocampus (DG) and the subventricular zone (SVZ) (27, 28). However, other regions have also been described as neurogenic niches, such as the hypothalamus or the striatum in some species (29–31). The SVZ in the lateral ventricles is a neuroepithelium that contains the specific conditions to form and maintain NSCs. NSCs could be differentiated into neurons or glial cells, such as astrocytes, oligodendrocytes, and neurons (**Figure 1A**), and share some specific characteristics with astrocytes (32). NSCs, also called type B cells, embed apical processes into the cerebrospinal fluid, and at the opposite side, embed their basal processes into blood vessels, creating a unique site to drive cell fate according to environmental signaling (33). NSCs are closely related to microglial cells within the SVZ as they are the primary macrophages of the CNS (34). In fact, microglia within the SVZ show a specific morphology, differential expression of some types of receptors, as well as some differences in expression of typical microglial markers such as Iba1, which is underexpressed (35, 36). Furthermore, some studies revealed that microglia release several factors that stimulate migration (37), promote the generation of neuroblasts (38), and enhance not only neurogenesis but also oligodendrogenesis (39). In fact, microglial cells are related to synaptic connectivity, programmed cell death, and regulation of neuronal activity (40–42). All things considered; microglia are a crucial component for determination of NSC fate.

For many years, researchers focused their attention on the SVZ as a potential contributor to GB development. That is because 50%–60% of GB is related to the SVZ and is also associated with the short life expectancy typical of glioblastoma patients (43, 44). This relationship is likely to cause a multifocal diagnosis, as well as an NSC transformation to a new form of cancer cell called glioblastoma stem cells (GSCs) (45). In 2018, Lee et al. described the relationship between GB and its SVZ origin, directing their attention to GSC characteristics using




FIGURE 1 | Glioblastoma and the subventricular zone. Details of the subventricular zone (SVZ), microglia cells and its relationship with glioblastoma (GB). Type B cells, known as the resident neural stem cells (NSC) within the SVZ are postulated as an origin of glioblastoma stem cells (GSC) because of the accumulation of some mutations. Signaling pathways are modified in response of the changing cancer niche soluble factors that promote M2 microglial cells phenotype. **(A)** SVZ niche in physiological conditions. **(B)** SVZ niche in the GB context.

single-cell sequencing to show that some mutations could transform healthy cells into cancer cells (46) (**Figure 1B**). GSCs show similarities with NSCs, such as the capacity to form cell aggregates called neurospheres (47–49), and the expression of several markers such as nestin, Sox2, Musashi-1, or BMI1 (50, 51). It has been postulated that GSCs are responsible for resistance to medical treatments and chemotherapeutic agents such as temozolomide (TMZ) (52–55). GSCs are self-renewing and are important for other components in the tumor origin, such as the microglial cells. Glioma tissues suppress the secretion of some factors, such as TGF- α , IL-10, prostaglandin E2 and IL-14, that promote M2-like microglial phenotype polarization (56), which is implicated in some immune response downregulation processes (57). In tumor masses, M2 microglia are associated with protumorigenic activities that are capable of stimulating tumor growth through several cytokines and chemokines like IL-10, monocyte chemoattractant protein-1 (MCP-1/CCL2), some metalloproteinases (MMPs), and ARG1 (13, 42, 58, 59). These factors could affect cell behavior by enhancing the crosstalk between microglia and astrocytes.

Another point associated with the tumor origin is related to the hypoxic environment. In this respect, the Vascular Endothelial Growth Factor (VEGF) is important because it induces the proliferation and activation of microglia and the neural precursor cells are involved in its secretion (60–62).

Regarding GB, hypoxia induces angiogenesis and promotes GSCs self-renewal *via* VEGF secretion (63, 64).

Therefore, researchers are now focused on identifying alterations in the signaling pathways and looking for new therapeutic targets to treat GB, focusing on microglia and their relationship with the neurogenic niche.

ALTERED SIGNALING PATHWAYS IN MICROGLIA IN GLIOBLASTOMA

Various alterations have been described in GB signaling pathways that involved microglia (1). Walentynowicz et al. characterized the functional response and transcriptional activity in human and mouse microglial cultures with fresh human cell glioma-conditioned substrate. They found activated pathways related to immune evasion and TGF- β signaling (65). Brennan et al. performed a protein analysis in surgical glioma specimens to identify differential patterns of coordinated switch on between glioma-relevant signal transduction pathways, which revealed three patterns of protein expression and activation: Epidermal Growth Factor Receptor (EGFR) expression related to receptor mutation and amplification; stimulation of the platelet-derived growth factor (PDGF) pathway that is mediated by ligands; or loss of

Neurofibromatosis type I NF1 gene expression (66). In addition other researches have shown that the polarized M2 microglia induces the transcription of PDGF Receptor Beta in glioma cells and stimulates their motility capacity (67).

Furthermore, several alterations have also been described in signaling pathway of CCL2 chemokine receptor CCR2 and its major (CCL2/CCR2) GB (68). CCL2 is over-expressed in GB. Interestingly, the secretion level of this chemokine correlates with tumor grade. Glioma cells initially secrete low levels of CCL2 to chemotactically attract microglia cells, which increase CCL2 generation in the tumor environment. The amplified secretion of CCL2 by microglial cells recruits even more microglial cells into the tumor, stimulating the progression and development of the glioma (69).

Relevant findings from Hira et al. show that Mesenchymal Stem Cells (MSCs), expressing SDF-1 α and OPN, capture CXCR4-CD44 positive GSCs into GSC niches and protect them from chemotherapy and irradiation (12).

Another altered signaling pathway associated with a negative regulation of T-cells, promoted by microglia, is the Programmed cell Death protein 1 (PD-1), due to the overexpression of ligand Programmed cell Death-Ligand 1 (PD-L1), in GB cells. The PD1 pathway alteration increases the possibility of PD-1/PD-L1 binding in microglia, which is associated with an increased invasion of GB cells into the brain tissue (70).

In addition, blocking the myeloid checkpoint of Signal regulatory protein alpha (SIRP α)/CD47 has shown to be efficient improving tumor phagocytosis and thus decreasing tumor burden (71, 72). SIRP- α in microglia exerts action in the neuronal CD47 to repress microglial stimulation (73). SIRP- α has a receptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic region (74) that is phosphorylated after CD47-SIRP- α interaction, promoting the binding and activation of SHP-1 and SHP-2 [(Src 2 (SH2) -like domain possessing protein tyrosine phosphatases (PTP)], which inhibits phagocytosis by preventing myosin IIA deposition at the phagocytic synapse (75, 76). Hence, the documented overexpression of CD47 in GB tumor cells (71) favors the immunosuppressive characteristics of microglia in the tumor microenvironment.

EPIGENETIC MECHANISMS IN MICROGLIA IN THE CONTEXT OF GLIOBLASTOMA

The phenotype of microglia is characterized by its own expressed gene pattern. This transcriptional signature is modified when cells are stimulated by a signal, or under pathological conditions such as GB. In this context, under homeostatic conditions, microglia have a transcriptional spectrum of expression with a main signature consisting of *P2RY13*, *TMEM119*, *CX3CR1*, *P2RY12*, *CSF1R*, *MARCKS*, and *SELPLG* genes and a diminished expression of MHC class II and lipid metabolism genes (2, 3). In the context of GB, microglia present higher expression of proinflammatory and metabolic genes, including *SPP1*, *HLA-DR*, *TREM2*, *APOE*, *CD163*, *GPR56*, and several type

I interferon genes, which is substantially different from the genetic expression in homeostatic microglia (4). These changes in expression are modulated by epigenetic mechanisms that regulate the accessibility of genetic loci to transcriptional machinery, gene expression levels, and chromatin architecture without altering the sequences in the DNA (5). This can be demonstrated by treatment with Valproic acid, which inhibits class I HDAC catalysis, promotes proteasomal hydrolysis of HDAC2 and primary adult human microglia, and decreases phagocytosis and levels of PU.1 and CD45, indicating that the regulation of the phagocytic activity of the microglia is carried out by epigenetic mechanisms (6). These HDAC inhibitors (HDACi) have a proapoptotic effect on cancer cells, which involves the interruption of the mitochondrial membrane potential and the increasing of acetylation in the protein histone H3 (7).


Global hypomethylation has been reported in 80% of GB (8), showing intratumoral DNA methylation heterogeneity (9). DNA methylation is closely related to the response to temozolomide (TMZ) treatment, with O6-methylguanine-DNA methyltransferase (MGMT) being the only predictive biomarker for a patient's response to first-line chemotherapy with TMZ (10). Hypermethylated CpG in the promoter of the connexin 30 (*Cx30*) gene have also been established in grade III and IV GB, but not in grade I and II gliomas. This hypermethylated region is related to Sp1 and Ap2 expression factor recognition sites and it is correlated with progressive downregulation of *Cx30* mRNA and with the degree of GB (11).

MiR-138 has been found to effectively inhibit cell division in GB *in vitro* and tumorigenicity *in vivo* by arresting a transcription factor EZH2-mediated signaling loop (12). Inhibition of EZH2 in GB decreases the transcription of M2 profile and increases the expression of M1 related proteins in microglia cells (13). We still have a long way to understand the role that epigenetic modifications play in microglia in GB, but research effort is focused on bringing light to this issue (Figure 2).

A detailed view of gene expression of microglia under homeostatic conditions versus GB, supports the understanding of the dysregulation processes in this disease, and could help to find new GB therapeutic targets.

MICROGLIA AS A THERAPEUTIC TARGET FOR GLIOBLASTOMA

Tumor-associated microglia have been shown to be a key therapeutic target in GB (14) since microglia cells decline in animal experimental models reduces tumor growth (15). Thus, therapies based on microglia as a target could complement the treatments currently used against this disease. Among the molecules that block microglial/macrophages' infiltration of GSC-derived tumors, the integrin inhibitor arginine-glycine-aspartic acid (RGD) peptides have been shown to interfere with GSC-secreted periostin, thereby these peptides could suppress tumor growth and augment survival of GB-bearing animals (16).



Another strategy employed promotes the antitumor activities of GAMs. For example, in an experimental model of GSC tumors derived from humans implanted in non-obese mice with combined diabetic/severe immunodeficiency (NOD-SCID), it was shown that systemic administration of amphotericin B (AmpB) significantly reduces tumor growth and increases the chances of survival. In animals treated with AmpB, a greater tumor penetration of M1 macrophages and microglial cells was found (77), showing a significant positive regulation of iNOS, and resulting in a higher production of cytotoxic nitric oxide (NO). In these same experiments, positive effects of AmpB it was also found in immunocompetent C57BL/6 mice against very aggressive tumors from stem-enriched CD133 + GL261 glioma cells (17).

Additionally, mTORC plays a key role in the integration of c-MET and PDGFR α signal transduction that are co-activated with EGFR in the context of GB, and it has been shown that inhibition of mTOR activity in rat microglial cells can promote its antitumor properties while restricting its protumorigenic characteristics. Therefore, mTOR inhibitors have the potential to attack both glioblastoma and the protumor functions of GAMs (78–81).

Intracranial injection of a viral recombinant adeno-associated vector (rAAV2) expressing IL-12, induce an increased level of IL-12 in tumor-bearing animals, contributing to microglial penetration in the tumor and reactivation of GAMs' protective effects. This immunological reactivation of GAMs significantly decreases tumor growth and prolongs animal life (19).

An oncolytic virotherapy using Herpes simplex virus type 1 (HSV-1) has been authorized by the FDA for cancer therapy after the optimum completion of clinical trials (20). In GB, the

antitumor efficacy of oncolytic HSV-1 (oHSV-1) is determined, in part, by the amount of microglia/macrophages that phagocytize viruses with the ability to express reporter genes. Thus, viral replication was inhibited, forming an unpermissive OV barrier, and avoiding the spread of oHSV-1 in the glioma mass. The decrease in viral replication, in microglial cells, was related to the suppression of some viral genes by phosphorylation of STAT1/3, responsible for suppressing oHSV-1 replication in microglia/macrophages (21). Together, these strategies employ microglia as a promising therapeutic target in treating glioblastoma.

Microglia are executors of the innate immune response and are specialized in sensing and eliminating abnormal cells, however these cells can change their phenotype and become tumor-promoting cells due to the influence of tumor signals. As part of the tumor mass, tumor-associated macrophages (TAM) are interesting therapeutic target based on data that have shown that the antiphagocytic protein CD47 is increased on the surface of cancer cells, allowing them to evade the innate immune system. To avoid the interaction of CD47 with SIRP- α , it is used an anti-CD47 monoclonal antibody (mAb). In microglia cells, anti-CD47 could prevent the expression of their protumorigenic phenotype and turn them into a potential weapon, to arrest GB progression (72).

Stupp et al. In a study with 695 patients with glioblastoma who have completed their initial radio-chemotherapy, the combination of tumor treatment fields (TTFields) with maintenance chemotherapy using alkylating agent TMZ demonstrated a statistically significant improvement with a median overall survival of 20.9 months in this group vs. 16 months in the temozolomide-only group (HR, 0.63, 95% CI, 0.53–0.76, $P < 0.001$) (4).

Pang et al. demonstrated the ability of macrophages as cell carriers of drugs. Culture of RAW264.7 cells in presence of LPS and IFN- γ , shown that these molecules bind to Toll-like receptor 4 and the IFN- γ receptor respectively, activating and promoting the exocytosis of the drug loaded by these cells. Thus, they propose the use of patient-derived M1-type macrophages loaded *in vitro* with the drug of interest, and then transferring them back to the patient to treat GB (82).

CONCLUSION

Microglia and TAMs comprise up to 30% of cells in the brain tumor environment (56, 83–88). Microglia cells in the CNS are keys regulators of homeostasis, but their function in immunological surveillance of glioma cells remains little known. Tumor cells, through the expression of different surface and secreted molecules, modulate the phagocytic activity of microglia by altering various signaling pathways and epigenetic mechanisms. Therefore, the modulation and reeducation of the set of microglia constitute a promising antitumor strategy against glioblastoma.

AUTHOR CONTRIBUTIONS

NG-D and EN conceptualized the study. IS-G and CF contributed to the methodology. LG and IS-G conducted the formal analysis. RN conducted the investigation. EN provided

the resources. NG-D and EN was in charge of the data curation. RN, CF, NG-D, and EN wrote and prepared the original draft. RN, AS, CF, LG, EP, IS-G, NG-D, and EN wrote, reviewed, and edited the manuscript. IS-G and NG-D created the cartoon in **Figures 1** and **2**. All authors contributed to the article and approved the submitted version.

FUNDING

We declare that the funds or sources of support received in this specific internal report study were from the Univesidad Simón Bolívar, Clinica de la Costa, Colombia, and Universidad de Cádiz, España, and that the external funding was from the Ministry of Science, Technology And Innovation of Colombia—COLCIENCIAS, subsidy 125380763038 and 125380763188 to EQ. We clarified that the funder had no role in the design of the study, in the collection and analysis of data, in the decision to publish, or in the preparation of the manuscript.

ACKNOWLEDGMENTS

The research was supported by the Universidad Simón Bolívar, Universidad de Cádiz, and Clinica de la Costa. The views expressed are those of the authors. Some images in the figures were obtained and modified via SMART: Service Medical ART (<http://smart.servier.com>).

REFERENCES

- Bowman RL, Klemm F, Akkari L, Pyonteck SM, Sevenich L, Quail DF, et al. Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. *Cell Rep* (2016) 17:2445–59. doi: 10.1016/j.celrep.2016.10.052
- Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* (2005) 352:987–96. doi: 10.1056/NEJMoa043330
- Tamimi AF, Juweid M. Epidemiology and Outcome of Glioblastoma. In: *Glioblastoma*. (2017) Codon Publications. p. 143–53. doi: 10.15586/codon.glioblastoma.2017.ch8
- Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial. *JAMA - J Am Med Assoc* (2017) 318:2306–16. doi: 10.1001/jama.2017.18718
- Akhavan D, Alizadeh D, Wang D, Weist MR, Shepphird JK, Brown CE. CAR T cells for brain tumors: Lessons learned and road ahead. *Immunol Rev* (2019) 290:60–84. doi: 10.1111/imr.12773
- Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. *Clin Cancer Res* (2013) 19:764–72. doi: 10.1158/1078-0432.CCR-12-3002
- Holland EC. Glioblastoma multiforme: The terminator. *Proc Natl Acad Sci U S A* (2000) 97:6242–4. doi: 10.1073/pnas.97.12.6242
- Klopfenstein Q, Truntzer C, Vincent J, Ghiringhelli F. Cell lines and immune classification of glioblastoma define patient's prognosis. *Br J Cancer* (2019) 120:806–14. doi: 10.1038/s41416-019-0404-y
- Morantz RA, Wood GW, Foster M, Clark M, Gollahon K. Macrophages in experimental and human brain tumors. Part 2: Studies of the macrophage content of human brain tumors. *J Neurosurg* (1979) 50:305–11. doi: 10.3171/jns.1979.50.3.0305
- Quail DF, Joyce JA. The Microenvironmental Landscape of Brain Tumors. *Cancer Cell* (2017) 31:326–41. doi: 10.1016/j.ccell.2017.02.009
- Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO. Multidimensional communication in the microenvirons of glioblastoma. *Nat Rev Neurol* (2018) 14:1–14. doi: 10.1038/s41582-018-0025-8
- Hira VVV, Breznik B, Vittori M, Loncq de Jong A, Mlakar J, Oostra RJ, et al. Similarities Between Stem Cell Niches in Glioblastoma and Bone Marrow: Rays of Hope for Novel Treatment Strategies. *J Histochem Cytochem* (2020) 68:33–57. doi: 10.1369/0022155419878416
- Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. *Nat Neurosci* (2015) 19:20–7. doi: 10.1038/nn.4185
- Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. *Nat Rev Immunol* (2018) 18:225–42. doi: 10.1038/nri.2017.125
- Gabrusiewicz K, Ellert-Miklaszewska A, Lipko M, Sielska M, Frankowska M, Kaminska B. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. *PLoS One* (2011) 6:1–12. doi: 10.1371/journal.pone.0023902
- Li W, Graeber MB. The molecular profile of microglia under the influence of glioma. *Neuro Oncol* (2012) 14:958–78. doi: 10.1093/neuonc/nos116
- Brandenburg S, Müller A, Turkowski K, Radev YT, Rot S, Schmidt C, et al. Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors. *Acta Neuropathol* (2016) 131:365–78. doi: 10.1007/s00401-015-1529-6
- Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol* (2008) 8:958–69. doi: 10.1038/nri2448
- Grégoire H, Roncali L, Rousseau A, Chérel M, Delneste Y, Jeannin P, et al. Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma. *Front Pharmacol* (2020) 11:1–105. doi: 10.3389/fphar.2020.00368
- Patel AR, Ritzel R, McCullough LD, Liu F. Microglia and ischemic stroke: A double-edged sword. *Int J Physiol Pathophysiol Pharmacol* (2013) 5:73–90.
- Anfray C, Ummarino A, Andón FT, Allavena P. Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses. *Cells* (2019) 9:1–24. doi: 10.3390/cells9010046

22. Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. *J Neuroinflammation* (2014) 11:1–15. doi: 10.1186/1742-2094-11-98
23. Zeiner PS, Preusse C, Golebiewska A, Zinke J, Iriondo A, Muller A, et al. Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas. *Brain Pathol* (2019) 29:513–29. doi: 10.1111/bpa.12690
24. Sørensen MD, Dahlrot RH, Boldt HB, Hansen S, Kristensen BW. Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype. *Neuropathol Appl Neurobiol* (2018) 44:185–206. doi: 10.1111/nan.12428
25. Caponegro MD, Moffitt RA, Tsirka SE. Expression of neuropilin-1 is linked to glioma associated microglia and macrophages and correlates with unfavorable prognosis in high grade gliomas. *Oncotarget* (2018) 9:35655–65. doi: 10.18632/oncotarget.26273
26. Zhou J, Reddy MV, Wilson BKJ, Blair DA, Taha A, Frampton CM, et al. MR Imaging Characteristics Associate with Tumor-Associated Macrophages in Glioblastoma and Provide an Improved Signature for Survival Prognostication. *Am J Neuroradiol* (2018) 39:252–9. doi: 10.3174/ajnr.A5441
27. Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: Age-related decrease of neuronal progenitor proliferation. *J Neurosci* (1996) 16:2027–33. doi: 10.1523/jneurosci.16-06-02027.1996
28. Doetsch F, Garcia-Verdugo JM, Alvarez-Buylla A. Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. *J Neurosci* (1997) 17:5046–61. doi: 10.1523/JNEUROSCI.17-13-05046.1997
29. Yuan T-F, Arias-Carrion O. Adult Neurogenesis in the Hypothalamus: Evidence, Functions and Implications. *CNS Neurol Disord Drug Targets* (2012) 10:433–9. doi: 10.2174/187152711795563985
30. Ernst A, Alkass K, Bernard S, Salehpour M, Perl S, Tisdale J, et al. Neurogenesis in the Striatum of the Adult Human Brain. *Cell* (2014) 156:1072–83. doi: 10.1016/j.cell.2014.01.044
31. Luzzati F, Nato G, Oboti L, Vigna E, Rolando C, Armentano M, et al. Quiescent neuronal progenitors are activated in the juvenile guinea pig lateral striatum and give rise to transient neurons. *Development* (2014) 141:4065–75. doi: 10.1242/dev.107987
32. Doetsch F, Caillé I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. *Cell* (1999) 97:703–16.
33. Mirzadeh Z, Merkle FT, Soriano-Navarro M, Garcia-Verdugo JM, Alvarez-Buylla A. Neural stem cells confer unique pinwheel architecture to the ventricular surface in neurogenic regions of the adult brain. *Cell Stem Cell* (2008) 3:265–78. doi: 10.1016/j.stem.2008.07.004
34. Gonzalez-Perez O, Gutierrez-Fernandez F, Lopez-Virgen V, Collas-Aguilar J, Quinones-Hinojosa A, Garcia-Verdugo JM. Immunological regulation of neurogenic niches in the adult brain. *Neuroscience* (2012) 226:270–81. doi: 10.1016/j.neuroscience.2012.08.053
35. Ribeiro Xavier AL, Kress BT, Goldman SA, Lacerda de Menezes JR, Nedergaard M. A Distinct Population of Microglia Supports Adult Neurogenesis in the Subventricular Zone. *J Neurosci* (2015) 35:11848–61. doi: 10.1523/JNEUROSCI.1217-15.2015
36. Xavier AL, Lima FRS, Nedergaard M, Menezes JRL. Ontogeny of CX3CR1-EGFP expressing cells unveil microglia as an integral component of the postnatal subventricular zone. *Front Cell Neurosci* (2015) 9:37. doi: 10.3389/fncel.2015.00037
37. Aarum J, Sandberg K, Haerberlein SLB, Persson MAA. Migration and differentiation of neural precursor cells can be directed by microglia. *Proc Natl Acad Sci USA* (2003) 100:15983–8. doi: 10.1073/pnas.2237050100
38. Walton NM, Sutter BM, Laywell ED, Levkoff LH, Kearns SM, Marshall GP, et al. Microglia instruct subventricular zone neurogenesis. *Glia* (2006) 54:815–25. doi: 10.1002/glia.20419
39. Shigemoto-Mogami Y, Hoshikawa K, Goldman JE, Sekino Y, Sato K. Microglia enhance neurogenesis and oligodendrogenesis in the early postnatal subventricular zone. *J Neurosci* (2014) 34:2231–43. doi: 10.1523/JNEUROSCI.1619-13.2014
40. Biber K, Neumann H, Inoue K, Boddeke HWGM. Neuronal “On” and “Off” signals control microglia. *Trends Neurosci* (2007) 30:596–602. doi: 10.1016/j.tins.2007.08.007
41. De Bock M, Vandenbroucke RE, Decrock E, Culot M, Cecchelli R, Leybaert L. A new angle on blood-CNS interfaces: A role for connexins? *FEBS Lett (Elsevier)* (2014) 1259–70. doi: 10.1016/j.febslet.2014.02.060
42. Zhang I, Alizadeh D, Liang J, Zhang L, Gao H, Song Y, et al. Characterization of arginase expression in glioma-associated microglia and macrophages. *PLoS One* (2016) 11:1–16. doi: 10.1371/journal.pone.0165118
43. Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. *Neuro Oncol* (2013) 15:91–6. doi: 10.1093/neuonc/nos268
44. Adeberg S, Bostel T, König L, Welzel T, Debus J, Combs SE. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: A predictive factor for survival? *Radiat Oncol* (2014) 9:1–6. doi: 10.1186/1748-717X-9-95
45. Sonoda Y, Ryuta S, Kanamori M, Kumabe T, Uenohara H, Tominaga T. The association of subventricular zone involvement at recurrence with survival after repeat surgery in patients with recurrent glioblastoma. *Neurol Med Chir (Tokyo)* (2014) 54:302–9. doi: 10.2176/nmc.oa.2013-0226
46. Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. *Nature* (2018) 560:243–7. doi: 10.1038/s41586-018-0389-3
47. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. *Glia* (2002) 39:193–206. doi: 10.1002/glia.10094
48. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. *Cancer Res* (2004) 64:7011–21. doi: 10.1158/0008-5472.CAN-04-1364
49. Yuan X, Curtin J, Xiong Y, Liu G, Waschmann-Hogiu S, Farkas DL, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. *Oncogene* (2004) 23:9392–400. doi: 10.1038/sj.onc.1208311
50. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, et al. Cancerous stem cells can arise from pediatric brain tumors. *Proc Natl Acad Sci USA* (2003) 100:15178–83. doi: 10.1073/pnas.2036535100
51. Sanai N, Alvarez-Buylla A, Berger MS. Mechanisms of disease: Neural stem cells and the origin of gliomas. *N Engl J Med* (2005) 353:811–22. doi: 10.1056/NEJMra043666
52. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. *Nature* (2004) 432:396–401. doi: 10.1038/nature03128
53. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* (2006) 444:756–60. doi: 10.1038/nature05236
54. Lathia JD, Gallagher J, Myers JT, Li M, Vasanji A, McLendon RE, et al. Direct In Vivo evidence for tumor propagation by glioblastoma cancer stem cells. *PLoS One* (2011) 6:1–9. doi: 10.1371/journal.pone.0024807
55. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. *Nature* (2012) 488:522–6. doi: 10.1038/nature11287
56. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. *Glia* (2011) 59:1169–80. doi: 10.1002/glia.21136
57. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. *Front Biosci* (2008) 13:453–61. doi: 10.2741/2692
58. Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. *Cancer Res* (2016) 76:5671–82. doi: 10.1158/0008-5472.CAN-16-0144
59. Lisi L, Ciotti GMP, Braun D, Kalinin S, Currò D, Dello Russo C, et al. Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma. *Neurosci Lett* (2017) 645:106–12. doi: 10.1016/j.neulet.2017.02.076
60. Mosher KI, Andres RH, Fukuhara T, Bieri G, Hasegawa-Moriyama M, He Y, et al. Neural progenitor cells regulate microglia functions and activity. *Nat Neurosci* (2012) 15:1485–7. doi: 10.1038/nn.3233
61. Morado-Diaz CJ, Matarredona ER, Morcuende S, Talaverón R, Davis-López de Carrizosa MA, de la Cruz RR, et al. Neural progenitor cell implants in the lesioned medial longitudinal fascicle of adult cats regulate synaptic

- composition and firing properties of abducens internuclear neurons. *J Neurosci* (2014) 34:7007–17. doi: 10.1523/JNEUROSCI.4231-13.2014
62. Talaverón R, Matarredona ER, de la Cruz RR, Macías D, Gálvez V, Pastor AM. Implanted neural progenitor cells regulate glial reaction to brain injury and establish gap junctions with host glial cells. *Glia* (2014) 62:623–38. doi: 10.1002/glia.22630
 63. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. *Cancer Res* (2009) 69:7243–51. doi: 10.1158/0008-5472.CAN-09-0167
 64. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. *Am J Pathol* (2010) 177:1491–502. doi: 10.2353/ajpath.2010.091021
 65. Walentynowicz KA, Ochocka N, Pasierbinska M, Wojnicki K, Stepniak K, Mieczkowski J, et al. In search for reliable markers of glioma-induced polarization of microglia. *Front Immunol* (2018) 9:1329. doi: 10.3389/fimmu.2018.01329
 66. Brennan C, Momota H, Hambarzumyan D, Ozawa T, Tandon A, Pedraza A, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. *PLoS One* (2009) 4:1–10. doi: 10.1371/journal.pone.0007752
 67. Wallmann T, Zhang XM, Wallerius M, Bolin S, Joly AL, Sobocki C, et al. Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity. *iScience* (2018) 9:71–83. doi: 10.1016/j.isci.2018.10.011
 68. Zhang J, Sarkar S, Cua R, Zhou Y, Hader W, Wee Yong V. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. *Carcinogenesis* (2012) 33:312–9. doi: 10.1093/carcin/bgr289
 69. Yoshimura T. The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments. *Cytokine* (2017) 98:71–8. doi: 10.1016/j.cyto.2017.02.001
 70. Litak J, Mazurek M, Grochowski C, Kamiński P, Roliński J. PD-L1/PD-1 axis in glioblastoma multiforme. *Int J Mol Sci* (2019) 20:1–16. doi: 10.3390/ijms20215347
 71. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. *Proc Natl Acad Sci USA* (2012) 109:6662–7. doi: 10.1073/pnas.1121623109
 72. Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. *Sci Transl Med* (2017) 9:1–13. doi: 10.1126/scitranslmed.aaf2968
 73. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. *Nat Rev Immunol* (2011) 11:775–87. doi: 10.1038/nri3086
 74. Barclay AN, Hatherley D. The Counterbalance Theory for Evolution and Function of Paired Receptors. *Immunity* (2008) 29:675–8. doi: 10.1016/j.immuni.2008.10.004
 75. Fujioka Y, Matozaki T, Noguchi T, Iwamatsu A, Yamao T, Takahashi N, et al. A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. *Mol Cell Biol* (1996) 16:6887–99. doi: 10.1128/mcb.16.12.6887
 76. Timms JF, Carlberg K, Gu H, Chen H, Kamatkar S, Nadler MJS, et al. Identification of Major Binding Proteins and Substrates for the SH2-Containing Protein Tyrosine Phosphatase SHP-1 in Macrophages. *Mol Cell Biol* (1998) 18:3838–50. doi: 10.1128/mcb.18.7.3838
 77. Sarkar S, Döring A, Zemp FJ, Silva C, Lun X, Wang X, et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. *Nat Neurosci* (2014) 17:46–55. doi: 10.1038/nn.3597
 78. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogiannis GM, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* (2008) 455:1061–8. doi: 10.1038/nature07385
 79. Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, et al. EGFR signals to mTOR through PKC and independently of Akt in glioma. *Sci Signal* (2009) 2:1–9. doi: 10.1126/scisignal.2000014
 80. Gulati P, Gaspers LD, Dann SG, Joaquin M, Nobukuni T, Natt F, et al. Amino Acids Activate mTOR Complex 1 via Ca²⁺/CaM Signaling to hVps34. *Cell Metab* (2008) 7:456–65. doi: 10.1016/j.cmet.2008.03.002
 81. Guo D, Cloughesy TF, Radu CG, Mischel PS. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. *Cell Cycle* (2010) 9:211–2. doi: 10.4161/cc.9.2.10540
 82. Pang L, Qin J, Han L, Zhao W, Liang J, Xie Z, et al. Exploiting macrophages as targeted carrier to guide nanoparticles into glioma. *Oncotarget* (2016) 7:37081–91. doi: 10.18632/oncotarget.9464
 83. Glass R, Synowitz M. CNS macrophages and peripheral myeloid cells in brain tumours. *Acta Neuropathol* (2014) 128:347–62. doi: 10.1007/s00401-014-1274-2
 84. Roggendorf W, Strupp S, Paulus W. Distribution and characterization of microglia/macrophages in human brain tumors. *Acta Neuropathol* (1996) 92:288–93. doi: 10.1007/s004010050520
 85. Badie B, Scharfner JM. Flow Cytometric Characterization of Tumor-associated Macrophages in Experimental Gliomas. *Neurosurgery* (2000) 46:957–62. doi: 10.1097/00006123-200004000-00035
 86. Gutmann DH, Kettenmann H. Microglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology. *Neuron* (2019) 104:442–9. doi: 10.1016/j.neuron.2019.08.028
 87. Carvalho Da Fonseca AC, Badie B. Microglia and macrophages in malignant gliomas: Recent discoveries and implications for promising therapies. *Clin Dev Immunol* (2013) 2013:1–5. doi: 10.1155/2013/264124
 88. Russo CD, Cappoli N. Glioma associated microglia/macrophages, a potential pharmacological target to promote antitumor inflammatory immune response in the treatment of glioblastoma. *Neuroimmunol Neuroinflammation* (2018) 5:36. doi: 10.20517/2347-8659.2018.42

Conflict of Interest: Authors LG and EN were employed by company Care4You.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Geribaldi-Doldán, Fernández-Ponce, Quiroz, Sánchez-Gomar, Escorcia, Velásquez and Quiroz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.